Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marwan Fakih

Showing results (141-150 of 200) with videos related to

Pageof 20
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|July 8, 2020
Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case SeriesRahel Demisse, Neha Damle, Edward Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responsesNicola R Hardwick, Mary Carroll, Teodora Kaltcheva, et al.
British Journal of Cancer|April 22, 2023
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumorsJason J Luke, Marwan Fakih, Charles Schneider, et al.
Cancer Chemotherapy and Pharmacology|July 29, 2022
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignanciesPatrick M Boland, Christos Fountzilas, Marwan Fakih, et al.
The Oncologist|December 21, 2019
A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver MetastasesChongkai Wang, John Park, Ching Ouyang, et al.
The Lancet. Oncology|April 21, 2019
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trialCathy Eng, Tae Won Kim, Johanna Bendell, et al.
Clinical Colorectal Cancer|May 18, 2024
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and DRichard Kim, Mustapha Tehfe, Petr Kavan, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomenKilian Salerno May, Nikhil I Khushalani, Rameela Chandrasekhar, et al.
Cancer Chemotherapy and Pharmacology|September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
Communications Medicine|July 20, 2022
Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancerChen Li, Ana Ferro, Shivani K Mhatre, et al.
Pageof 20

Showing results (141-150 of 200) with videos related to

Sort By:
Pageof 20
Journal of the National Comprehensive Cancer Network : JNCCN|July 8, 2020
Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case SeriesRahel Demisse, Neha Damle, Edward Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responsesNicola R Hardwick, Mary Carroll, Teodora Kaltcheva, et al.
British Journal of Cancer|April 22, 2023
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumorsJason J Luke, Marwan Fakih, Charles Schneider, et al.
Cancer Chemotherapy and Pharmacology|July 29, 2022
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignanciesPatrick M Boland, Christos Fountzilas, Marwan Fakih, et al.
The Oncologist|December 21, 2019
A Pilot Feasibility Study of Yttrium-90 Liver Radioembolization Followed by Durvalumab and Tremelimumab in Patients with Microsatellite Stable Colorectal Cancer Liver MetastasesChongkai Wang, John Park, Ching Ouyang, et al.
The Lancet. Oncology|April 21, 2019
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trialCathy Eng, Tae Won Kim, Johanna Bendell, et al.
Clinical Colorectal Cancer|May 18, 2024
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and DRichard Kim, Mustapha Tehfe, Petr Kavan, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomenKilian Salerno May, Nikhil I Khushalani, Rameela Chandrasekhar, et al.
Cancer Chemotherapy and Pharmacology|September 1, 2005
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancersRamesh K Ramanathan, Marwan Fakih, Sridhar Mani, et al.
Communications Medicine|July 20, 2022
Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancerChen Li, Ana Ferro, Shivani K Mhatre, et al.
Pageof 20